Another predictor of resistance to cetuximab in wt-RAS CRC has been indicated in EPH2A, a receptor involved in multiple cross-talks with other cellular networks, including EGFR, FAK, and VEGF pathways. Here, EGFR is linked to colorectal carcinoma.